• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Association of cardiac and non-cardiac comorbidities with adverse outcomes of atrial fibrillation

byDavy LauandAlex Chan
October 27, 2021
in Cardiology, Chronic Disease
Reading Time: 2 mins read
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Share on FacebookShare on Twitter

1. A cluster analysis of European atrial fibrillation (AF) patients found that both cardiac and non-cardiac comorbidities were associated with a greater risk of adverse outcomes.

Evidence Rating Level: 2 (Good)

Atrial Fibrillation (AF) is a multifactorial condition associated with numerous risk factors and co-morbidities. These include cardiovascular (CV) comorbidities, such as heart failure, stroke, and coronary artery disease, as well as non-CV conditions, such as diabetes mellitus and chronic kidney disease. Due to the multitude of clinical phenotypes associated with AF, cluster analysis can be used to identify which phenotypes are at greater risk of adverse outcomes and mortality. This data analytics technique has been used in studying other CV conditions, but has seldom been applied to study AF. The current study is the largest observational non-industry of AF patients in Europe, known as the EORP-AF: Their aim involved identifying relevant multi-morbidity clinical phenotypes of AF, along with evaluating differences in clinical management, use of resources, and adverse outcomes. From the 9363 patients included in the analysis, three clusters were identified: Cluster 1 consisted of older patients with non-CV comorbidities (median [IQR] age of 73 [65-78] years), younger patients with few comorbidities (median [IQR] age 65 [56-72] years), and older patients with high prevalence of CV comorbidities and risk factors (median [IQR] age 73 [66-78] years). The study found that in terms of AF management, Cluster 3 had the highest use of antiplatelet drugs (p < 0.001), and oral anticoagulants (OACs) were lowest in Cluster 2 (p < 0.001). As well, a rate control strategy was more common in Cluster 2, whereas a rhythm control strategy was more common in Cluster 2 (p < 0.001). Within the mean [SD] length of hospital stay was lowest in Cluster 2 (4.36 [6.33] days), followed by Cluster 1 (6.52 [7.29] days), with the highest in Cluster 3 (8.07 [8.50] days), with differences between each cluster being significant (p < 0.001). In terms of adverse outcomes, such as CV events, all-cause death, and a composite score of the two, the lowest rate of events was found in Cluster 2, followed by Cluster 1 and 3 respectively. Compared to Cluster 2, the hazards ratio for the composite score was 2.09 in Cluster 1 (95% CI 1.74-2.51) and 2.79 in Cluster 3 (95% CI 2.32-3.35). Overall, this study demonstrated that the presence of comorbidities in older AF patients, whether CV or non-CV, were associated with a greater risk of adverse outcomes, compared to younger patients with few comorbidities. 

Click to read the study in BMC Medicine

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Increased rapid eye movement (REM) sleep is associated with lower risks of several chronic diseases

Chronic exposure to particulate matter is associated with increased cardiovascular risk

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

Tags: atrial fibrillationcardiology
Previous Post

Daily 12 mg dexamethasone not superior to 6 mg for severe COVID-19 infection

Next Post

#VisualAbstract: Adjuvant atezolizumab shows benefit in patients with stage II-IIIA non-small-cell lung cancer

RelatedReports

Cardiology

Increased rapid eye movement (REM) sleep is associated with lower risks of several chronic diseases

September 23, 2026
Cardiology

Chronic exposure to particulate matter is associated with increased cardiovascular risk

September 10, 2026
Nephrology

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

September 9, 2026
Long-term outcomes for off-pump and on-pump CABG are similar
Weekly Rewinds

2 Minute Medicine Rewind September 7, 2026

September 7, 2026
Next Post
#VisualAbstract: Adjuvant atezolizumab shows benefit in patients with stage II-IIIA non-small-cell lung cancer

#VisualAbstract: Adjuvant atezolizumab shows benefit in patients with stage II-IIIA non-small-cell lung cancer

#VisualAbstract: Implant-based breast reconstruction with acellular dermal matrix does not reduce reoperation rates

#VisualAbstract: Gemcitabine plus cisplatin improves overall survival compared to fluorouracil plus cisplatin in metastatic or recurrent nasopharyngeal carcinoma

Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial

Rivaroxaban superior to aspirin at reducing recurrent stroke in patients with embolic stroke of undetermined source and left ventricular dysfunction: (NAVIGATE ESUS Trial)

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Prognostic associations of anthropometric indices vary by clinical outcomes
  • Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma
  • Gene therapy shows sustained benefit in Wiskott–Aldrich syndrome
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.